Browsing by Author "Solomon, Benjamin J."

Now showing items 1-2 of 2

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

Solomon, Benjamin J.; Zhou, Cai Cun; Drilon, Alexander; Park, Keunchil; Wolf, Jurgen; Elamin, Yasir; Davis, Hannah M.; Soldatenkova, Victoria; Sashegyi, Andreas; Lin, Aimee Bence; Lin, Boris K.; Loong, Herbert H. F.; Novello, Silvia; Arriola Aperribay, Edurne; Pérol, Maurice; Goto, Koichi; Santini, Fernando C. (Future Medicine Ltd., 2021)

Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell ...
Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: Findings from the PACIFIC-R study

Girard, Nicolas; Taus García, Álvaro; Solomon, Benjamin J. (Elsevier, 2023)

Introduction: The phase 3 PACIFIC trial established consolidation therapy with durvalumab as standard of care for patients with unresectable, stage III NSCLC and no disease progression after definitive chemoradiotherapy ...

Now showing items 1-2 of 2

Search DSpace

In collaboration with Compliant to Partaking